1. Introduction

Commercial Genetic Data Platforms are digital businesses that collect, process, analyse, store, license, and commercially exploit genetic information obtained from individuals, hospitals, research institutions, biotechnology companies, pharmaceutical manufacturers, and diagnostic laboratories.

Examples include platforms providing:

Direct-to-consumer DNA testing.

Genetic ancestry and genealogy services.

Genetic disease-risk prediction.

Personalised medicine and pharmacogenomic analysis.

Genetic database subscriptions.

Licensing of anonymised or pseudonymised genomic datasets.

AI-based genetic research and drug discovery.

Sale or licensing of genetic insights to pharmaceutical and biotechnology companies.

Taxation of these platforms raises complex legal questions because genetic data can have several commercial characteristics simultaneously: personal information, a research resource, a digital asset, a service input, and a source of intellectual property.

The central taxation question is whether revenue generated from genetic information should be treated as income from services, licensing, intellectual property, digital business operations, data transactions, or research and development.

Tax authorities must also address indirect taxation, international transactions, transfer pricing, withholding tax, tax deductions, research incentives, and the valuation of genetic databases.

2. Legal Nature of Genetic Data as a Taxable Commercial Asset

The first difficulty is determining the legal and economic character of genetic data.

A commercial genetic platform may receive revenue from several different activities:

An important legal distinction: Genetic information does not automatically become taxable royalty merely because it has commercial value. The contractual rights transferred, the nature of the information, the intellectual property involved, and the applicable tax treaty determine its classification.

For example, granting a pharmaceutical company limited access to a searchable genetic database is different from transferring ownership of the database, licensing proprietary analytical software, or disclosing confidential scientific know-how.

This distinction becomes particularly important in cross-border transactions.

3. Taxation Under Indian Income-Tax Law

India provides an important framework for taxing commercial genetic data platforms through business-income provisions, royalty rules, international taxation, and transfer-pricing regulations.

A. Business income

Income earned through ordinary commercial activities may be classified as business income.

Examples include:

Subscription charges for genetic testing.

Fees for processing DNA samples.

Revenue from ancestry reports.

Charges for maintaining genetic databases.

Fees for genetic interpretation services.

Commercial contracts with pharmaceutical companies.

The relevant business profits are calculated after allowing deductions permitted under the applicable income-tax legislation.

Typical deductible expenditure may include:

Laboratory operating costs.

Employee salaries and professional fees.

Cloud storage and computing expenses.

Genetic sequencing equipment depreciation.

Software development expenses.

Database maintenance expenditure.

Qualifying research and development expenditure.

Cybersecurity and regulatory compliance costs.

However, the tax treatment of capital expenditure, software development, acquired intellectual property, and research expenditure must be determined separately.

B. Royalty taxation

Royalty classification is particularly important when a genetic data platform licenses:

Proprietary genetic databases.

Copyright-protected genomic software.

Patent-protected diagnostic technologies.

Proprietary genetic algorithms.

Scientific processes and confidential know-how.

Commercial or scientific information falling within the statutory definition.

Under the historical Income-tax Act, 1961, Section 9(1)(vi), Explanation 2 contains an extensive definition of royalty.

The corresponding provisions of the Income-tax Act, 2025, must be considered for transactions governed by the new legislation.

A payment for access to a genetic database should not automatically be treated as royalty. The actual rights granted must be examined.

9+1

C. International taxation

Suppose an American genetic database company provides subscriptions to Indian hospitals.

The following questions arise:

Is the subscription payment business income or royalty?

Does the company have a permanent establishment in India?

Does the applicable India–US tax treaty restrict India's taxation rights?

Is withholding tax required?

Does the payment represent a service or a licence of intellectual property?

These questions must be determined from the agreement, actual commercial conduct, domestic tax legislation, and applicable double taxation avoidance agreement (DTAA).

4. GST on Commercial Genetic Data Platforms

The Goods and Services Tax framework is relevant when genetic platforms supply testing, database access, digital analysis, and related services for consideration.

Under India's IGST Act, 2017, Section 2(17) defines Online Information and Database Access or Retrieval (OIDAR) services.

A digitally delivered genetic database subscription or automated genomic information service may fall within OIDAR, depending on its characteristics.

The distinction between automated digital services and laboratory services involving substantial human intervention is important.

Examples:

Automated access to a genomic database may qualify as OIDAR.

A laboratory conducting physical DNA sequencing may constitute a different category of service.

A genetic counselling service involving substantial professional intervention requires separate classification.

A bundled DNA-testing package may require examination of its principal supply and associated supplies.

GST registration, place-of-supply rules, export-of-services conditions, and reverse-charge obligations must also be examined.

Foreign suppliers providing qualifying OIDAR services to Indian non-taxable online recipients may have direct GST compliance obligations. The general GST rate commonly relevant to taxable services is 18%, subject to the applicable classification and notification.

wtocentre.iift.ac.in+1

5. Important Judicial Decisions and Case Laws

There is currently no established body of reported Indian tax judgments specifically addressing the taxation of commercial genomic databases. However, judicial decisions concerning digital databases, software licensing, royalty, and international digital services provide important principles for genetic-data businesses.

Case 1: Engineering Analysis Centre of Excellence Pvt. Ltd. v. Commissioner of Income Tax (2021)

Supreme Court of India

Citation: (2021) 432 ITR 471 (SC).

Legal issue: Whether payments made for the use of computer software amounted to royalty under Section 9(1)(vi) of the Income-tax Act, 1961 and relevant tax treaties.

Judgment: The Supreme Court examined the distinction between transferring copyright rights and merely permitting the use of copyrighted software. It held that payments in the relevant transactions did not constitute royalty where the necessary copyright rights had not been transferred.

Application to genetic data platforms:

A genetic database company may provide customers with access to proprietary software without transferring copyright ownership or reproduction rights.

Following the reasoning of this judgment, the mere provision of access to software does not automatically constitute royalty.

However, a genuine transfer of intellectual-property rights or scientific know-how may produce a different result.

Case 2: Commissioner of Income Tax v. RELX Inc. (2024)

Delhi High Court

Decision date: 7 February 2024.

Legal issue: Whether subscription charges received for providing access to an online database constituted royalty or fees for technical services.

Judgment: The Delhi High Court held that granting access to a database, without transferring copyright rights, did not constitute royalty under the relevant India–US DTAA. It also rejected the treatment of the subscription receipts as technical-service fees on the facts before it.

Indian Kanoon

Application to genetic data platforms:

This judgment is particularly relevant to commercial genomic databases.

For example, a platform may allow hospitals to search genetic research records, compare genomic information, and access scientific publications.

If customers merely receive limited database access without acquiring copyright rights or proprietary know-how, the subscription revenue may be treated as business income rather than royalty, subject to the applicable treaty and facts.

Case 3: Uptodate Inc. v. Deputy Commissioner of Income Tax (2023)

Citation: (2023) 150 taxmann.com 231 (Delhi Tribunal).

Legal issue: Whether subscription income from access to a specialised healthcare database was taxable as royalty under the India–US DTAA.

Judgment: The Tribunal considered the fact that the company compiled third-party information, organised and indexed it, and provided customers with restricted access. Customers were not permitted to reproduce, modify, or commercially exploit the underlying content.

The Tribunal held that the subscription receipts did not constitute royalty under the relevant treaty.

Digest of case laws

Application to genetic data platforms:

This decision can assist platforms that aggregate:

Genetic research publications.

Publicly available genomic information.

Disease-associated genetic records.

Scientific research datasets.

Clinical and diagnostic reference information.

It supports the argument that database access and the transfer of intellectual-property rights are legally distinct transactions.

Case 4: Amazon.com Inc. v. Commissioner of Internal Revenue (2019)

Court: United States Court of Appeals for the Ninth Circuit.

Legal issue: Valuation of intangible property transferred between related companies and application of transfer-pricing rules.

Judgment: The litigation addressed the valuation of intangible property and the application of the US transfer-pricing framework to intercompany transactions.

Application to genetic data platforms:

Multinational biotechnology businesses frequently transfer valuable genetic databases, software, algorithms, and research rights between subsidiaries.

These transactions require defensible valuations and appropriate allocation of income between related entities.

Justia Law+1

Case 5: Sabre Decision Technologies International Pvt. Ltd. v. Deputy Commissioner of Income Tax

Legal issue: Whether subscription payments for access to an electronic commercial database could constitute royalty or consideration for technical or commercial knowledge.

Legal significance: The dispute illustrates that tax authorities may examine the underlying technology, functionality, nature of information, and extent of rights granted rather than simply accepting the description of a payment as a database subscription.

Application to genetic data platforms:

A platform providing advanced genomic interpretation, proprietary analytical processes, or specialised scientific know-how may face a different royalty analysis from a platform that merely permits users to search a database.

The classification must therefore be based on the actual contractual and operational arrangements.

Note: These cases concern analogous digital and database transactions, not direct judicial determinations of genetic-data taxation.

6. Transfer Pricing and Commercial Genetic Databases

Transfer pricing is one of the most significant taxation issues for multinational genetic data companies.

Consider the following hypothetical arrangement:

An Indian subsidiary collects and processes genetic information.

A US parent company owns the commercial database.

A Singapore subsidiary manages the cloud infrastructure.

A European subsidiary licenses genomic datasets to pharmaceutical companies.

The tax authorities may investigate whether each company receives an appropriate share of the group's profits.

Under the Indian Income-tax Act, 1961, Sections 92–92F and associated rules establish the transfer-pricing framework for international transactions.

The Indian Income Tax Department identifies automated databases, software, trade secrets, and technical data as examples of intangible assets relevant to transfer pricing.

Rules, Compliance & TP Guide+1

Major transfer-pricing issues include:

Whether the Indian subsidiary owns or merely processes the genetic database.

Whether the parent company controls the valuable intellectual property.

Whether the Indian subsidiary performs valuable research activities.

Whether database development costs are appropriately allocated.

Whether royalty payments reflect arm's-length pricing.

Whether the group artificially shifts profits to low-tax jurisdictions.

The following methods may be relevant, depending on the transaction:

Comparable Uncontrolled Price Method (CUP).

Resale Price Method (RPM).

Cost Plus Method (CPM).

Transactional Net Margin Method (TNMM).

Profit Split Method (PSM).

Other Method, where permitted.

The Profit Split Method may be particularly relevant when several associated enterprises make unique and valuable contributions to developing a commercial genomic database.

7. Taxation of Genetic Database Valuation and Intellectual Property

Genetic databases can acquire substantial commercial value through the accumulation of research records, sequencing information, disease associations, and proprietary analytical systems.

Taxation becomes complicated when a company:

Purchases an existing genomic database.

Develops its own proprietary database.

Licenses genetic datasets to third parties.

Sells database access through subscriptions.

Transfers ownership of a genomic research business.

Contributes data-related intellectual property to a joint venture.

The tax authority must distinguish between the underlying information, the database structure, software, copyright, confidential know-how, and contractual rights.

For example, a company selling a complete business containing a genetic database may have a capital-gains or business-income issue, depending on the nature and structure of the transaction.

A recurring subscription for access to that same database may instead constitute operating revenue.

Important principle: The commercial value of genetic information does not, by itself, establish that the information is owned as intellectual property or that every transaction involving it is a royalty transaction.

8. Tax Deductions and Research and Development Incentives

Commercial genetic data platforms often incur substantial expenditure on scientific research and technological development.

Potentially relevant expenditure includes:

Companies must distinguish between routine business expenditure and expenditure that creates enduring assets.

In India, research and development expenditure must be assessed under the applicable provisions governing business deductions, scientific research, depreciation, and capital expenditure. No automatic deduction should be assumed merely because an activity is described as genetic research.

9. Cross-Border Taxation of Genetic Data Transactions

International genetic data platforms create several competing taxation claims.

For example, an Indian company may collect genetic samples, process genomic information in India, store the information on servers in Singapore, and license analytical results to a pharmaceutical company in the United States.

The following legal issues arise:

A. Permanent establishment

A foreign company may become taxable in India if its activities satisfy the applicable domestic-law and treaty requirements for a permanent establishment (PE).

Merely having Indian customers or remotely accessible servers does not automatically establish a PE.

B. Withholding tax

Payments made by Indian customers to foreign genetic database providers may require examination under applicable withholding-tax provisions.

The answer depends on whether the payments constitute royalty, fees for technical services, or business profits under the relevant law and DTAA.

C. Double taxation

The same commercial transaction may be examined by several countries.

Tax treaties, foreign tax credits, and mutual agreement procedures may help resolve overlapping taxation.

D. Transfer of genomic intellectual property

Where a multinational company transfers proprietary genetic algorithms or database rights between associated enterprises, the transaction requires appropriate valuation and transfer-pricing documentation.

10. Privacy Law and Its Relationship With Taxation

Genetic information presents an additional legal difficulty because it concerns highly personal biological characteristics.

Tax legislation should not be confused with legislation governing ownership, privacy, and commercial exploitation of genetic information.

In India, the Digital Personal Data Protection Act, 2023, and its applicable rules provide a framework for processing digital personal data.

Genetic information processed in identifiable form can raise significant data-protection concerns.

Commercial platforms should maintain:

Lawful processing arrangements.

Appropriate consent or other applicable legal grounds.

Data-processing agreements.

Security safeguards.

Retention and deletion policies.

Records of international data transfers.

Clear contractual arrangements with research partners.

A company cannot automatically claim unrestricted commercial ownership of individuals' genetic information simply because it has collected or stored that information.

This distinction has consequences for taxation because a platform's commercial revenue, intellectual-property rights, and lawful data-processing rights are separate legal questions.

11. Major Taxation Challenges

The principal challenges can be summarised as follows:

12. Suggested Regulatory and Tax Policy Reforms

A comprehensive taxation framework for commercial genetic data platforms should consider the following reforms.

1. Clear classification rules

Tax authorities should distinguish between genetic testing, database access, data licensing, scientific consultancy, and intellectual-property transfers.

2. Specific valuation standards

Guidelines should address the valuation of genomic databases, proprietary algorithms, and commercially developed genetic datasets.

3. International tax coordination

Countries should coordinate their rules for cross-border genomic research and licensing transactions to minimise double taxation and artificial profit shifting.

4. Research incentives

Tax incentives should support genuine genetic research, medical innovation, disease prevention, and biotechnology development.

5. Privacy-sensitive tax administration

Tax authorities should obtain only information necessary for legitimate tax administration and apply appropriate confidentiality and security safeguards.

6. Transparent contractual arrangements

Genetic platforms should clearly distinguish data-processing charges, database subscriptions, intellectual-property royalties, and scientific research fees.

13. Conclusion

Taxation of Commercial Genetic Data Platforms represents an emerging intersection of income-tax law, GST, international taxation, intellectual-property law, biotechnology regulation, and data protection.

The most important legal issue is the classification of revenue generated from genetic information.

A subscription for accessing a genetic database is not necessarily royalty. A transfer of proprietary genetic algorithms may involve intellectual-property licensing. Laboratory testing may constitute a separate taxable service. Multinational genetic data transactions may also require transfer-pricing adjustments.

The decisions in Engineering Analysis, RELX Inc., and Uptodate Inc. provide important judicial guidance on the distinction between database access and the transfer of intellectual-property rights.

Ultimately, an effective tax framework must protect legitimate government revenue while encouraging biotechnology research, responsible commercial innovation, international scientific collaboration, and individual genetic-data privacy.

14. Important Legal References

Useful primary and supporting references:

Delhi High Court – RELX Inc. (2024).

Uptodate Inc. – Database subscription decision.

Indian Income Tax Department – Transfer Pricing.

Income-tax provisions concerning royalty.

India – Digital Trade and taxation report.

Academic note: The analysis uses Indian law as its principal framework. The cited database and software cases are analogous authorities, not decisions directly concerning the taxation of genetic data platforms. For transactions after 1 April 2026, the applicable provisions of the Income-tax Act, 2025, should be checked rather than relying exclusively on section numbering from the 1961 Act.